Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

Who May Be Eligible (Plain English)

Who May Qualify: - Mentally capable of understanding and completing willing to sign a consent form for the study. - Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that an appropriate rapid test for SARS-CoV-2 was positive. - To qualify for long COVID group participants will need to have new, persistent symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18. Who Should NOT Join This Trial: - Subject is unable to provide willing to sign a consent form. - Primary Investigator or Sub-Investigator determines the participant's ongoing medical complaints that began after 1 November 2019 are not related to SARS-COV-2 but another disease process. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Mentally capable of understanding and completing informed consent for the study. * Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that an appropriate rapid test for SARS-CoV-2 was positive. * To qualify for long COVID group participants will need to have new, persistent symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18. Exclusion Criteria: * Subject is unable to provide informed consent. * Primary Investigator or Sub-Investigator determines the participant's ongoing medical complaints that began after 1 November 2019 are not related to SARS-COV-2 but another disease process.

Treatments Being Tested

DIAGNOSTIC_TEST

RNA Biomarker Blood Test

Blood will be collected into a PaxGene Blood tube for processing by sponsor

Locations (3)

University of Iowa
Iowa City, Iowa, United States
The MaxWell Clinic
Brentwood, Tennessee, United States
The MaxWell Clinic
Brentwood, Tennessee, United States